Search result for 'cdsco'

Renalyx Health Systems plans to invest Rs 800 crore in 3 dialysis machine manufacturing units, boosting India's healthcare sector. The company's AI-enabled RxT 21 machine targets wider access to...

Biocon receives CDSCO approval for its generic Liraglutide, a diabetes medication. The drug will be launched in India soon, expanding access to affordable treatment.

AstraZeneca India receives CDSCO approval for Osimertinib, a non-small cell lung cancer treatment. The drug offers a new treatment option for patients with Stage III NSCLC.

Eli Lilly India launches Mounjaro, a first-of-its-kind medication for obesity and type 2 diabetes, offering hope for millions in India struggling with these conditions.

Indian pharmaceutical exports ranked 11th globally in 2023, contributing 3% of total exports. The government emphasizes quality control and transparency in pricing.

Biovet, a subsidiary of Bharat Biotech, has received approval from CDSCO for its lumpy skin disease vaccine, Biolumpvaxin, marking a significant step towards India's veterinary healthcare...

Sanofi Healthcare India receives marketing authorization for Rezurock (Belumosudil), a new treatment for Chronic Graft-versus-Host Disease (cGVHD) in adults and adolescents.

Pune-based startup Atreya Innovations has developed an AI-powered pulse diagnostic tool for Ayurveda practitioners, 'Nadi Tarangini', which analyzes 22 health parameters and generates reports in...

India's Health Ministry grants MSME pharma companies an additional year to meet revised GMP standards under Schedule M, pushing the deadline to December 31, 2025. The decision comes after requests...

India witnessed a significant rise in drug recalls in 2023-24, with 1,394 batches failing quality tests. The Minister of State for Health revealed the data, highlighting concerns over drug quality.

A parliamentary committee highlights gaps in medical radiation device testing in India, urging reforms in the national testing infrastructure and increased capacity at the National Testing House...

India's medical technology industry is expected to reach USD 20 billion in exports by 2030, but needs government support for growth, says CII. The industry body highlights the need for more PLI...

Dr Reddy's Laboratories has launched BixiBat, a first-in-class drug for chronic constipation in India. The drug, Elobixibat, works by increasing bile acid concentration in the colon, leading to...

Medical device industry slams import of refurbished equipment, calling it a threat to 'Make in India' initiative and patient safety.

Wockhardt receives a favourable recommendation from CDSCO for its novel antibiotic, Miqnaf, designed for treating community-acquired bacterial pneumonia (CABP) in adults.

India's drug regulator clarifies on recall of substandard medicines and action against fake drug manufacturers. Learn about the difference between 'not of standard quality' and 'spurious' medicines.

The Indian Pharmaceutical Alliance (IPA) expresses concern over linking spurious drugs with legitimate manufacturers, emphasizing severe reputational and financial consequences. The organization...

Leading pharma companies like Sun Pharma and Torrent Pharma have denied manufacturing drugs flagged by CDSCO as 'not of standard quality', claiming they are counterfeits.

Entod Pharmaceuticals receives DCGI approval for PresVu eye drops, the first in India to treat presbyopia, a common age-related vision condition. The company plans to launch the product in India in...

Siemens Healthineers receives CDSCO approval for its Monkeypox detection RT-PCR kit, enabling faster diagnosis and contributing to the fight against the public health emergency. The kit is...

Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus (RSV) in infants and children up to 24 months.

Serum Institute of India (SII) acquires 20% stake in IntegriMedical, a company developing a needle-free injection system. The technology aims to revolutionize vaccine administration, offering a...

Boehringer Ingelheim receives approval for Spevigo (Spesolimab), a first-in-class treatment for Generalised Pustular Psoriasis (GPP) flares in adults in India.

Sanofi India has launched its diabetes drug Soliqua, a combination of insulin glargine and lixisenatide, offering a once-daily injectable treatment option for adults with type 2 diabetes.

Cipla receives CDSCO approval for plazomicin, a new intravenous antibiotic for treating complicated urinary tract infections (CUTI), including pyelonephritis.

Pfizer and Glenmark Pharmaceuticals have partnered to launch abrocitinib, a treatment for atopic dermatitis, in India. The drug is approved by CDSCO, FDA, and EMA.